Search
Ethaselen
go.drugbank.com/drugs/DB15051InvestigationalEthaselen is under investigation in clinical trial NCT02166242 (Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers).
D-Tyrosine
go.drugbank.com/drugs/DB03839ExperimentalIn animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium
go.drugbank.com/drugs/DB02648ExperimentalIt is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
Talnetant
go.drugbank.com/drugs/DB06429InvestigationalTalnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the tr...
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. … The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with
TPX-4589
go.drugbank.com/drugs/DB18604InvestigationalTPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
Olaparib-bodipy FL
go.drugbank.com/drugs/DB16263InvestigationalOlaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).
Octovalent O-polysaccharide-toxin A conjugate vaccine
go.drugbank.com/drugs/DB17789ExperimentalOctovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.[A259462]
Eftilagimod alfa
go.drugbank.com/drugs/DB16150InvestigationalEftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).